Our verdict is Uncertain significance. Variant got 1 ACMG points: 2P and 1B. PM2BP6
The NM_000368.5(TSC1):āc.1096C>Gā(p.Pro366Ala) variant causes a missense change. The variant allele was found at a frequency of 0.0000031 in 1,614,022 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
TSC1 (HGNC:12362): (TSC complex subunit 1) This gene is a tumor suppressor gene that encodes the growth inhibitory protein hamartin. The encoded protein interacts with and stabilizes the GTPase activating protein tuberin. This hamartin-tuberin complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. This protein also functions as a co-chaperone for Hsp90 that inhibits its ATPase activity. This protein functions as a facilitator of Hsp90-mediated folding of kinase and non-kinase clients, including TSC2 and thereby preventing their ubiquitination and proteasomal degradation. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]
Verdict is Uncertain_significance. Variant got 1 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP6
Variant 9-132911047-G-C is Benign according to our data. Variant chr9-132911047-G-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 411229.We mark this variant Likely_benign, oryginal submissions are: {Benign=1, Uncertain_significance=1}.
Review Status: criteria provided, single submitter
Collection Method: clinical testing
The p.P366A variant (also known as c.1096C>G), located in coding exon 9 of the TSC1 gene, results from a C to G substitution at nucleotide position 1096. The proline at codon 366 is replaced by alanine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Tuberous sclerosis 1 Benign:1
Jul 30, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Loss of catalytic residue at P366 (P = 0.0173);.;Loss of catalytic residue at P366 (P = 0.0173);Loss of catalytic residue at P366 (P = 0.0173);Loss of catalytic residue at P366 (P = 0.0173);Loss of catalytic residue at P366 (P = 0.0173);Loss of catalytic residue at P366 (P = 0.0173);Loss of catalytic residue at P366 (P = 0.0173);Loss of catalytic residue at P366 (P = 0.0173);.;Loss of catalytic residue at P366 (P = 0.0173);Loss of catalytic residue at P366 (P = 0.0173);Loss of catalytic residue at P366 (P = 0.0173);Loss of catalytic residue at P366 (P = 0.0173);.;